Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-6 trans-signaling miniprotein
- Development stage
- Preclinical
- Lead developer
- VRG Therapeutics
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
VRG Therapeutics is developing a miniprotein therapeutic designed to selectively inhibit IL-6 trans-signaling for the treatment of chronic inflammatory and autoimmune diseases. Developed using the company's AI-powered miniprotein platform (AI-MPRO) and WISDOM technology, this candidate aims to block the pro-inflammatory trans-signaling pathway (mediated by the soluble IL-6 receptor) while preserving the homeostatic classical signaling pathway (mediated by the membrane-bound IL-6 receptor). This selectivity is intended to reduce the side effects associated with global IL-6 inhibition, such as increased infection risk and neutropenia. Miniproteins are small, disulfide-stabilized peptides that combine the high affinity and specificity of monoclonal antibodies with the stability and potential for oral delivery characteristic of small molecules. The program is currently in the early research stage.
- Other names
- IL-6 trans-signaling inhibitorIL6 trans-signaling inhibitorIL 6 trans-signaling inhibitorVRG Therapeutics IL-6 program
02
Targets
IL-6 (Interleukin 6)
Beyond the preview
Go deeper on IL-6 trans-signaling miniprotein.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-6 trans-signaling miniprotein.